NCT01921816View on ClinicalTrials.gov

A Study on the Efficacy and Safety of Continuous Renal Replacement Therapy (CVVHDF) Using a Commercial Citrate-containing Replacement Fluid (Prismocitrate 18/0)

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2013

Conditions
Renal Failure
Interventions
DEVICE

Prismocitrate 18/0, Prism0cal

Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk

Trial Locations (1)

852

Adult Intensive Care unit, Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT01921816 - A Study on the Efficacy and Safety of Continuous Renal Replacement Therapy (CVVHDF) Using a Commercial Citrate-containing Replacement Fluid (Prismocitrate 18/0) | Biotech Hunter | Biotech Hunter